Science Daily7h
Co-located cell types help drive aggressive brain tumors
A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.
precisionmedicineonline8h
Immuneering Partners with Regeneron to Study Combined MEK, PD-1 Inhibitor Therapy in Solid Tumors
NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
The stock's fall snapped a three-day winning streak.
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Regeneron Pharmaceuticals REGN +0.75% Get Free Report has outperformed the market over the past 20 years by 17.78% on an annualized basis producing an average annual return of 26.11%. Currently, ...
Armed robbery in Revesby12h
Cell Types Co-located Drive Aggressive Brain Tumors
A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...
Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
BioSpace17h
Regeneron Sues Sanofi, Alleging Stonewalling in Dupixent Pact
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
SHAREHOLDER DEADLINE: Regeneron Pharmaceuticals (REGN) Investors Are Reminded of Deadline in Securities Action
On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...